AI Article Synopsis

  • A study evaluated the clinical outcomes of patients requiring short dual antiplatelet therapy (S-DAPT) after receiving a Cre8 polymer-free amphilimus eluting stent (AES) to assess its safety and effectiveness.
  • The analysis involved two groups: one with patients on S-DAPT due to high bleeding risk (106 patients) and another on the recommended longer dual antiplatelet therapy (R-DAPT, 1102 patients).
  • Results showed no significant difference in major ischemic events between the groups at one year, but the S-DAPT group had a higher rate of major bleeding within the first three months; further research through randomized trials is suggested to confirm these findings.

Article Abstract

Background: To assess clinical outcomes of patients needing short dual antiplatelet therapy (S-DAPT) after PCI with Cre8 polymer-free amphilimus eluting-stent (AES). The Cre8-AES with pure i-Carbofilm coating was supposed to induce faster stent endothelialization and reduce device thrombogenicity.

Methods: We performed a sub-analysis of unrestricted consecutive patients treated with Cre8-AES between August 2011 and January 2015. Two groups were formed: 1) patients discharged with S-DAPT (≤3-month), because of high bleeding risk or attending urgent non-cardiac surgery; and 2) patients discharged with Recommended DAPT duration (R-DAPT; ≥6-month). The primary ischemic- and bleeding-safety endpoints were Target Vessel Failure (TVF, composite endpoint of cardiac-death, target vessel-myocardial infarction and target vessel-revascularization), and major-bleeding (BARC ≥type-3a) at 6-month and 1-year.

Results: 106 patients (8.7%) were discharged with ≤3-month DAPT (83±19days; S-DAPT group) and 1102 patients (90.6%) with ≥6-month DAPT (342±62days; R-DAPT group). Between S-DAPT and R-DAPT groups no significant differences were observed in TVF at 1-year (5.7% vs 5.1%); 1-year BARC major bleeding rate was higher in S-DAPT group (3.4% vs 0.2%, p=0.007) with all bleeding events occurred within 3months. The landmark analysis (started at 90days, ended at 1year) showed no differences in BARC major bleedings between groups (0% vs. 0.3%).

Conclusions: The results of this multicenter registry show that the use of Cre8 AES in patients needing short DAPT (≤3-month) was safe regarding ischemic events and could favor a reduction of bleeding events related to the recommended DAPT. A large randomized trial is necessary to support these preliminary findings.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2017.01.023DOI Listing

Publication Analysis

Top Keywords

patients needing
12
needing short
12
patients
8
short dual
8
dual antiplatelet
8
antiplatelet therapy
8
multicenter registry
8
patients discharged
8
recommended dapt
8
s-dapt group
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!